Revium Rx (RVRC) Price to Earnings (2025 - 2026)
Revium Rx's (RVRC) quarterly Price to Earnings came in at 138.55 in Q2 2026, down 327.99% year-over-year from 60.77 in Q2 2025, and down 327.99% quarter-over-quarter from 32.37 in Q2 2025.
Powered by 
Analysis
Revium Rx (RVRC) Price to Earnings (2025 - 2026) Analysis & Trends
Revium Rx has disclosed Price to Earnings across 2 years of filings, most recently posting 138.55 for Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Revium Rx | 86.84 Mn | 85.34 Mn | - |